Page 1

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 10 - K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number 012-34567 OR Delaware ( State or other jurisdiction of incorporation or organization ) Tarsus TARSUS PHARMACEUTICALS , INC . ( Exact name of Registrant as specified in its charter ) 15440 Laguna Canyon Road , Suite 160 Irvine , California ( Address of principal executive offices ) Securities registered pursuant to Section 12 ( b ) of the Act : Title of each class Common Stock , $ 0.0001 par value per share ( 949 ) 409-9820 ( Registrant's telephone number , including area code ) to Trading Symbol TARS 81-4717861 ( I.R.S. Employer Identification Number ) 92618 ( Zip Code ) Name of each exchange on which registered The Nasdaq Global Market LLC ( Nasdaq Global Select Market ) Securities registered pursuant to Section 12 ( g ) of the Act : None . Indicate by check mark if the registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15 ( d ) of the Act . Yes No Indicate by check mark whether the registrant ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . Yes No